Late-btear dupixent® (dupilumab) i.eata at the ERS 2022 show consistent eeffectiveness and security profile to the andp to tsore jears clean cchildren aAges 6 to 11 jears with moderate-to-sever astma
- The results of the longest global, open-label, phase 3 extension study in this age group in asthma show sustained improvement in lung function, a low rate of asthma attacks and a consistent safety profile for up to two years
- The data support Dupixent’s well-established efficacy and safety profile across all age groups
Paris and Tarrytown, New York 5th September2022. Results from an open-label phase 3 extension study demonstrated Dupixent’s efficacy and safety profile® (Dupilumab) as maintenance therapy in combination with other asthma medications has been consistent for up to two years in children ages 6 to 11 with uncontrolled moderate to severe asthma with evidence of type 2 inflammation. These findings were presented today in a landmark session at the 2022 European Respiratory Society (ERS) International Congress, coinciding with the milestone that more than 500,000 people around the world have been treated with Dupixent in its approved indications.
Leonard B. bacharian, md
Professor of Pediatrics, Director, Center for Pediatric Asthma Research, Monroe Carell Jr. Children’s Hospital, Vanderbilt University Medical Center
“Persistent cough and difficulty breathing may occur in children with uncontrolled moderate to severe asthma, unpredictable asthma attacks and affectdling function that can lead to complications later in life as they grow and develop. When treating children with a chronic disease, an established safety profile balanced with efficacy is always a priorityB. those with uncontrolled moderate to severe asthma with an eosinophilic phenotype or oral corticosteroid-dependent asthma. These new data support Dupixent’s consistent long-term safety profile, intended for the treatment of uncontrolled moderate to severe asthma with a…
